Hemonc simplified

Dr. Balla
  • 5.0(1개의 평가)
  • 가이드
  • 매일 업데이트

This podcast is all about hematology and has simplified the subject matter for medical students, residents, and hematologists. This podcast is for educational purposes only and does not constitute medical advice. Consult your healthcare provider for personal medical concerns

에피소드

  1. 3일 전

    004. Flow cytometry demystified

    Ready to master the ultimate diagnostic tool in hematopathology? In this episode of HemOnc Simplified, we crack open the flow cytometer to turn complex scatter plots and antibody markers into high-yield, intuitive clinical frameworks. Whether you are preparing for your USMLE exams, pathology boards, or clinical hematology rotations, this episode breaks down the core concepts you absolutely must know: The "City Analogy": Understand the fundamental difference between Flow Cytometry and Immunohistochemistry (IHC). Flow cytometry "demolishes the city" by dissociating the tissue into individual cell suspensions to interview thousands of cellular residents, while IHC "leaves the city standing" to preserve crucial tissue architecture.Deciphering Scatter: Learn how Forward Scatter (FSC) measures cell size and Side Scatter (SSC) measures internal complexity and granularity (and why granules increase side scatter, not forward scatter).The CD5+ B-Cell Differential: A step-by-step roadmap to differentiate Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) from Mantle Cell Lymphoma (MCL). We break down the clinical significance of CD23, CD200, marker intensity (the diagnostic contrast between "dim" and "bright" CD20/surface Ig), and the pathognomonic \(t(11;14)\) translocation.The CD10+ Germinal-Center Phenotype: How to use BCL2, the Ki-67 proliferation index, and genetics (\(t(14;18)\) vs. \(t(8;14)\)) to distinguish Follicular Lymphoma from the highly aggressive Burkitt Lymphoma.Rapid-Fire Board Mnemonics: Memorize the classic "cheat codes," including the "11c-25-103" signature for Hairy Cell Leukemia and the "123-4-56" trick for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).Clonal Spectrum in LPL: Understand how Lymphoplasmacytic Lymphoma (LPL) exhibits plasmacytic differentiation, showing a clonal B-cell and plasma-cell component that share the same light-chain restriction, often driven by the MYD88 L265P mutation.The "Negative Flow" Trap: Why a negative flow study does not rule out lymphoma. We explain how fragile cells (like in Diffuse Large B-Cell Lymphoma) can easily burst during processing, and why the rare Reed-Sternberg cells of Classic Hodgkin Lymphoma are nearly impossible to capture on routine flow plots.0:00 - Welcome to HemOnc Simplified!1:15 - Phenotype vs. Genetics: What Flow Can and Cannot Tell You2:45 - FSC vs. SSC: Size vs. Granularity4:15 - The "City Analogy": Flow vs. IHC6:00 - CLL/SLL vs. Mantle Cell Lymphoma (CD5+ Differential)9:15 - Follicular vs. Burkitt Lymphoma (CD10+ Phenotypes)12:00 - Board Shortcuts: Hairy Cell Leukemia, BPDCN, and LPL15:30 - Beware the "Negative Flow" Trap!The content of this podcast is designed strictly for academic, educational, and board-review purposes. Hematopathology and oncology are highly complex, rapidly evolving specialties. Clinical diagnoses and patient management must never be based on a single laboratory parameter and should always be validated against official peer-reviewed literature, updated clinical guidelines (such as the NCCN), and institutional diagnostic protocols.

  2. 7월 17일

    003. Immune checkpoint inhibitors and related side effects

    "HemOnc Simplified: Navigating the 2026 NCCN Guidelines for Immunotherapy Toxicities." How do we manage the "collateral damage" when the immune system turns against the body? In this episode, we dive deep into the 2026 NCCN Clinical Practice Guidelines for the Management of Immune Checkpoint Inhibitor-Related Toxicities. In this episode, we cover: The Biology of "Releasing the Brakes": Why blocking CTLA-4 and PD-1 proteins allows T cells to attack cancer but also triggers inflammatory immune-related adverse events (irAEs).The "Big Two" (Skin & Gut): Management protocols for maculopapular rashes and colitis, including the 2026 criteria for holding therapy and escalating to biologics.Emergency Alert: The "3 M’s": How to rapidly identify the life-threatening overlap syndrome of Myocarditis, Myositis, and Myasthenia Gravis, and why pulse steroids are a must.The 2026 Steroid-Sparing Toolkit: New recommendations for agents like dupilumab for bullous pemphigoid and the expanded role of IVIG and plasmapheresis in neurologic events.The Rechallenge Roadmap: Clinical principles for determining when it is safe to resume immunotherapy and when permanent discontinuation is mandatory.Tune in to stay at the forefront of patient safety in the age of precision immuno-oncology! ⚠️ Disclaimer: This audio content is for educational purposes only and does not constitute medical advice. Oncology is a rapidly evolving field; clinicians should always refer to the full NCCN Clinical Practice Guidelines and their specific institutional protocols for all clinical decision-making.

  3. 7월 15일

    002. Rewriting the Genetic Rulebook for Leukemia

    The "genetic rulebook" for Acute Myeloid Leukemia (AML) has undergone a fundamental transformation, shifting the focus of diagnosis and treatment from how cells look under a microscope (morphology) to their underlying molecular and cytogenetic signatures. This evolution is codified in the competing 2022 classification systems from the World Health Organization (WHO) and the International Consensus Classification (ICC), as well as the updated 2022 European LeukemiaNet (ELN) risk stratification. One of the most significant changes in the modern rulebook is the de-emphasis of the traditional 20% blast threshold for diagnosis. WHO 2022: Eliminates the blast threshold entirely for specific entities, such as AML with mutated NPM1 or translocations involving KMT2A, NUP98, and MECOM.ICC 2022: Reduces the requirement to 10% blasts for these defining genetic abnormalities and introduces a new category called MDS/AML for cases with 10% to 19% blasts that harbor specific MDS-associated mutations.Exceptions: Both systems still require a 20% blast count for AML with the BCR::ABL1 fusion to distinguish it from the accelerated phase of Chronic Myeloid Leukemia.The 2022 ELN guidelines have "rewritten" how specific mutations determine a patient’s prognosis: The FLT3-ITD Shift: Previously, the FLT3-ITD allelic ratio was critical for determining risk. The new rulebook categorizes all FLT3-ITD (without other adverse lesions) as intermediate risk, regardless of the ratio or concurrent NPM1 status. This change is due to the standardization difficulties of the allelic ratio and the availability of targeted FLT3 inhibitors like midostaurin and quizartinib.The CEBPA Refinement: Risk is no longer tied to whether a mutation is biallelic. Instead, any in-frame mutation in the basic leucine zipper (bZIP) region of CEBPA is now considered favorable risk.New Adverse Markers: The adverse-risk category has expanded to include a specific set of myelodysplasia-related mutations (e.g., ASXL1, BCOR, SF3B1, SRSF2), even if the physical signs of myelodysplasia are absent.TP53 Dominance: Mutations in TP53 (with a variant allele fraction $\ge$10%) remain a hallmark of adverse risk, often associated with complex karyotypes and very poor outcomes.The genetic rulebook now serves as a primary roadmap for selecting targeted therapies: FLT3 Mutations: Fit patients receive intensive chemotherapy plus a FLT3 inhibitor (midostaurin for ITD/TKD or quizartinib for ITD only).CD33 Expression: Patients with favorable-risk AML that is CD33-positive may have gemtuzumab ozogamicin added to their induction.IDH1/2 Mutations: While these mutations do not carry a specific prognostic weight, they are vital "targets" for inhibitors like ivosidenib.KMT2A and NPM1: Emerging treatments like menin inhibitors (e.g., revumenib) specifically target the biology driven by these alterations.Finally, the modern rulebook acknowledges that a patient's Measurable Residual Disease (MRD) status can override their initial genetic risk. For example, a patient with a "favorable" NPM1 mutation who remains MRD-positive after induction is now treated as high-risk, making them a candidate for allogeneic stem cell transplantation. 📢 Disclaimer The content on this channel is intended for educational and informational purposes only. It should not be considered medical advice or a substitute for professional clinical judgment. Clinical decisions should always be based on individual patient circumstances, current evidence, and applicable guidelines. Patients should consult their healthcare providers for personalized medical advice.

  4. 7월 14일

    001. AML Management and Board Review Strategy

    Welcome to this educational podcast on Acute Myeloid Leukemia (AML). The information presented in this podcast is intended solely for educational and informational purposes. It is based on current medical literature, published clinical guidelines, and the source material used in preparing this episode. Medical knowledge continues to evolve, and recommendations may change as new evidence becomes available. This podcast is not intended to replace professional medical advice, diagnosis, or treatment. Healthcare professionals should use their own clinical judgment and consult the latest guidelines, institutional protocols, and prescribing information before making patient care decisions. Patients and caregivers should always seek advice from their treating physician or qualified healthcare provider regarding any medical condition or treatment. The views expressed in this podcast are educational in nature and do not necessarily represent the official policies of any hospital, university, or professional organization. Mention of specific medications, diagnostic tests, or treatment strategies does not constitute an endorsement. Thank you for joining us as we explore the rapidly evolving field of Acute Myeloid Leukemia and evidence-based advances in diagnosis, risk stratification, and treatment. This video serves as a comprehensive medical guide for the diagnosis, classification, and management of Acute Myeloid Leukemia (AML), specifically tailored for board examinations. It details the ELN 2022 risk stratification, which categorizes patients into favorable, intermediate, or adverse groups based on molecular genetics rather than just blast counts. The sources emphasize the necessity of targeted therapies, such as adding FLT3 inhibitors to the standard "7+3" chemotherapy backbone or utilizing venetoclax-based regimens for unfit patients. Critical medical emergencies are highlighted, particularly the immediate administration of ATRA for suspected APL to prevent fatal coagulopathy. Additionally, the text underscores the importance of Measurable Residual Disease (MRD) monitoring, noting that its presence can shift a favorable prognosis toward a recommendation for a stem cell transplant. Overall, the material functions as an essential algorithm for navigating modern AML treatment paradigms and identifying key genetic mutations that influence clinical outcomes.

  • 4개의 에피소드

소개

This podcast is all about hematology and has simplified the subject matter for medical students, residents, and hematologists. This podcast is for educational purposes only and does not constitute medical advice. Consult your healthcare provider for personal medical concerns

정보

  • 제작진
    Dr. Balla
  • 방송 연도
    2026년
  • 에피소드
    4
  • 등급
    전체 연령 사용가
  • 저작권
    © Dr. Balla
  • 웹사이트 보기
    Hemonc simplified